Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them.
Company profile
Ticker
CRL
Exchange
Website
CEO
James Foster
Employees
Location
Fiscal year end
Industry (SIC)
PPD • IQVIA • PRA Health Sciences • Syneos Health • Icon • Medpace • Zymergen • Incyte • SomaLogic • National Research ...
Former names
CHARLES RIVER LABORATORIES HOLDINGS INC, CHARLES RIVER LABORATORIES INTERNATIONAL INC
SEC CIK
Corporate docs
Subsidiaries
Charles River Laboratories, Inc. • Charles River UK Limited • Charles River Laboratories Saint‑Constant S.A. • Charles River Nederland B.V. • Charles River Laboratories Holding SAS • Charles River Laboratories France C.R.L.F. SAS • BioFocus DPI (Holdings) Ltd. • Charles River Laboratories Belgium SRL • Charles River Laboratories España SA • Charles River Germany Verwaltungs GmbH ...
IRS number
61397316
CRL stock data
Analyst ratings and price targets
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
6 Dec 22
8-K
Regulation FD Disclosure
30 Nov 22
10-Q
2022 Q3
Quarterly report
2 Nov 22
8-K
Results of Operations and Financial Condition
2 Nov 22
10-Q
2022 Q2
Quarterly report
3 Aug 22
8-K
Results of Operations and Financial Condition
3 Aug 22
8-K
Regulation FD Disclosure
8 Jun 22
SD
Conflict minerals disclosure
26 May 22
8-K
Submission of Matters to a Vote of Security Holders
12 May 22
10-Q
2022 Q1
Quarterly report
4 May 22
Transcripts
CRL
Earnings call transcript
2022 Q3
2 Nov 22
CRL
Earnings call transcript
2022 Q2
3 Aug 22
CRL
Earnings call transcript
2022 Q1
4 May 22
CRL
Earnings call transcript
2021 Q4
17 Feb 22
CRL
Earnings call transcript
2021 Q3
3 Nov 21
CRL
Earnings call transcript
2021 Q2
5 Aug 21
CRL
Earnings call transcript
2021 Q1
4 May 21
CRL
Earnings call transcript
2020 Q4
17 Feb 21
CRL
Earnings call transcript
2020 Q3
31 Oct 20
CRL
Earnings call transcript
2020 Q3
29 Oct 20
Latest ownership filings
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 196.18 mm | 196.18 mm | 196.18 mm | 196.18 mm | 196.18 mm | 196.18 mm |
| Cash burn (monthly) | 3.68 mm | 2.53 mm | (no burn) | (no burn) | (no burn) | (no burn) |
| Cash used (since last report) | 16.05 mm | 11.03 mm | n/a | n/a | n/a | n/a |
| Cash remaining | 180.12 mm | 185.14 mm | n/a | n/a | n/a | n/a |
| Runway (months of cash) | 49.0 | 73.3 | n/a | n/a | n/a | n/a |
Institutional ownership, Q3 2022
93.8% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 570 |
| Opened positions | 63 |
| Closed positions | 110 |
| Increased positions | 229 |
| Reduced positions | 196 |
| 13F shares | Current |
|---|---|
| Total value | 9.39 bn |
| Total shares | 47.70 mm |
| Total puts | 66.00 k |
| Total calls | 140.60 k |
| Total put/call ratio | 0.5 |
| Largest owners | Shares | Value |
|---|---|---|
| Vanguard | 5.98 mm | $1.18 bn |
| BLK Blackrock | 5.31 mm | $1.04 bn |
| Kayne Anderson Rudnick Investment Management | 1.63 mm | $321.23 mm |
| T. Rowe Price | 1.59 mm | $312.22 mm |
| Clearbridge Advisors | 1.45 mm | $285.27 mm |
| IVZ Invesco | 1.03 mm | $201.89 mm |
| Geode Capital Management | 994.91 k | $195.57 mm |
| Allspring Global Investments | 976.35 k | $192.14 mm |
| Jackson Square Partners | 870.79 k | $171.37 mm |
| FMR | 739.78 k | $145.59 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 31 Jan 23 | Victoria L Creamer | Common Stock | Payment of exercise | Dispose F | No | No | 244.29 | 2,692 | 657.63 k | 15,496 |
| 27 Jan 23 | Knell Michael Gunnar | Common Stock | Payment of exercise | Dispose F | No | No | 244.29 | 645 | 157.57 k | 7,889 |
| 27 Jan 23 | Knell Michael Gunnar | Common Stock | Grant | Acquire A | No | No | 0 | 2,096 | 0.00 | 8,534 |
| 27 Jan 23 | LaPlume Joseph W | Common Stock | Payment of exercise | Dispose F | No | No | 244.29 | 3,261 | 796.63 k | 25,647 |
| 27 Jan 23 | LaPlume Joseph W | Common Stock | Grant | Acquire A | No | No | 0 | 8,676 | 0.00 | 28,908 |
| 27 Jan 23 | Girshick Birgit | Common Stock | Payment of exercise | Dispose F | No | No | 244.29 | 3,153 | 770.25 k | 41,038 |
| 27 Jan 23 | Girshick Birgit | Common Stock | Grant | Acquire A | No | No | 0 | 8,435 | 0.00 | 44,191 |
| 27 Jan 23 | William D Barbo | Common Stock | Payment of exercise | Dispose F | No | No | 244.29 | 2,897 | 707.71 k | 8,763 |
| 27 Jan 23 | William D Barbo | Common Stock | Grant | Acquire A | No | No | 0 | 7,857 | 0.00 | 11,660 |
| 27 Jan 23 | Victoria L Creamer | Common Stock | Grant | Acquire A | No | No | 0 | 7,229 | 0.00 | 18,188 |
News
Jim Cramer Says This Stock Is Undervalued: 'I Think That It's Coming Back'
2 Feb 23
Charles River Laboratories, AbbVie, Star Bulk Carriers And This Big Bank Are CNBC's 'Final Trades'
23 Jan 23
This Favorable Sign Appears On Charles River's Chart
19 Jan 23
Charles River And Rznomics Announce RNA-based Anticancer Gene Therapy Manufacturing Alliance
18 Jan 23
What Does Charles River's Debt Look Like?
12 Jan 23
Press releases
Charles River Launches CliniPrime Suite of GMP-Compliant Cellular Products
16 Jan 23
Charles River Establishes eXpDNA™ Plasmid Manufacturing Platform to Expedite DNA Programs
12 Jan 23
Charles River Laboratories to Present at J.P. Morgan Healthcare Conference
9 Jan 23
Arlington Capital Partners Announces the Acquisition of AVS Bio
5 Jan 23
Charles River Laboratories Adds Craig B. Thompson, M.D. to Board of Directors
6 Dec 22